A descriptive retrospective cohort study assessing rate of recurrent Guillain-Barré Syndrome after mRNA COVID-19 vaccine BNT162b2
Latest Information Update: 09 Sep 2021
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 09 Sep 2021 New trial record
- 01 Sep 2021 Results published in the JAMA Neurology